Inclusion body myositis: Clinical and pathological boundaries
- 8 October 1996
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 40 (4) , 581-586
- https://doi.org/10.1002/ana.410400407
Abstract
Inclusion body myositis, polymyositis, and dermatomyositis are three distinct categories of inflammatory myopathy. Some authorities commented on the selective early weakness of the volar forearm muscles, quadriceps, and ankle dorsiflexors in inclusion body myositis. The most important feature distinguishing inclusion body myositis from the other two inflammatory myopathies is the lack of responsiveness to immunosuppressive treatment. Although most patients with inclusion body myosities have characteristic muscle biopsy findings, some cannot be distinguished histologically early from polymyositis. Presdicting responsiveness to mmunosuppressive medications, independent of muscle histology, would be valuable to clinicians. We retrospectively reviewed the pattern of weakness and other clinical features of 46 patients newly diagnosed with either inclusion body myositis, polymyositis, or dermatomyosities. Asymmetrical muscle weakness with prominent wrist flexor, finger flexor, and knee extensor involvement was specific for inclusion body myositis and unresponsive polymyositis. Male sex, lower creatine kinase levels, slower rate of progression, and peripheral neuropathy were also more common in inclusion body myositis and unresponsive polymyositis than in responsive polymyositis and dermatomyositis patients. Repeat muscle biopsy in 2 patients in teh unresponsive polymyositis group demonstrated histological features of inclusion body myositis. We suspect that patients with clinical features of inclusion body myositis but lacking histological confirmation may nonetheless have inclusion body myositis. Our study supports the recently proposed criteria for defintie and possible inclusion body myositis.Keywords
This publication has 18 references indexed in Scilit:
- The Treatment of Inclusion Body MyositisMedicine, 1993
- Treatment of inclusion‐body myositis with high‐dose intravenous immunoglobulinNeurology, 1993
- Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacyThe American Journal of Medicine, 1993
- Amyloid Filaments in Inclusion Body MyositisArchives of Neurology, 1991
- Polymyositis, Dermatomyositis, and Inclusion-Body MyositisNew England Journal of Medicine, 1991
- The Relationship of Complement-Mediated Microvasculopathy to the Histologic Features and Clinical Duration of Disease in DermatomyositisArchives of Neurology, 1991
- Microvascular changes in early and advanced dermatomyositis: A quantitative studyAnnals of Neurology, 1990
- Microvascular Deposition of Complement Membrane Attack Complex in DermatomyositisNew England Journal of Medicine, 1986
- Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cellsAnnals of Neurology, 1984
- Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositisAnnals of Neurology, 1984